This clinical trial against breast cancer has analyzed the potential anti-tumor role of denosumab, a drug already in use in the prevention of metastasis-related osteoporosis and bone lesions.

Denosumab, a drug commonly used to treat osteoporosis and prevent bone complications in cancer patients, is being investigated for a potential new application in breast cancer treatment. Early results ...

Among patients with severe postmenopausal osteoporosis unresponsive to long-term denosumab, addition of romosozumab improved lumbar spine bone mineral density. Denosumab combined with romosozumab ...

of the European Medicines Agency has issued positive opinions on its denosumab biosimilars - Vevzuo and Denosumab BBL- recommending its approval for distinct therapeutic indications for bone ...

The US Food and Drug Administration (FDA) has approved denosumab-bnht (Conexxence/Bomyntra), manufactured by Fresenius Kabi, for all indications of the reference ...

On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), referencing Amgen’s PROLIA® and XGEVA®, respectively.

Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal women with osteoporosis. Denosumab treatment ...

The study included 2 treatment periods. During the first period, study participants (N=479) were randomly assigned 1:1 to receive denosumab-bmwo or the reference product. Patients who received the ...

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations. Stoboclo and ...

The FDA approved denosumab-bmwo for all indications of the reference drugs Prolia and Xgeva. According to a settlement between Amgen and Celltrion, the biosimilars can be launched as early as June 1.

Clinical studies confirmed equivalent efficacy, safety, and pharmacokinetics between denosumab biosimilars and reference products. Common adverse events for Ospomyv include back pain and ...